摘要
目的:评价树突状细胞联合自体细胞因子诱导杀伤细胞( DC/CIK)维持治疗晚期非小细胞肺癌( NSCLC)的疗效和不良反应。方法根据治疗情况将2010年1月至2014年1月120例含铂方案化疗4~6个周期后疾病稳定的晚期NSCLC患者分为对照组( n=65)和研究组( n=55),仅研究组化疗后接受DC/CIK维持治疗。对两组进行生存随访并比较中位无进展生存期( PFS)和总生存期( OS),同时记录不良反应情况。结果研究组的中位PFS为5.0个月,高于对照组的3.5个月,差异有统计学意义(P<0.05);研究组的中位OS为8.5个月,与对照组(8.0个月)的差异无统计学意义(P>0.05);两组化疗后获不同疗效亚组中位PFS和OS的差异均无统计学意义( P>0.05)。常见不良反应为骨髓抑制、发热、乏力和关节酸痛,两组不良反应发生率的差异无统计学意义( P>0.05)。结论 DC/CIK维持治疗可延长化疗后疾病稳定晚期NSCLC患者的进展时间,且不良反应轻,患者可耐受。
Objective To evaluate the toxicity and efficacy of dendritic cells/cytokine-induced killer cells ( DC/CIK) as the maintenance therapy for advanced non-small cell lung cancer ( NSCLC) . Methods During January 2010 and January 2014, 120 ad-vanced NSCLC patients in stable condition were enrolled after 4-6 cycles chemotherapy containing platinum. According to the treatment, patients were assigned into control group ( n=65) and study group ( n=55) . Only the study group received DC/CIK maintenance ther-apy. Both groups were followed up and the progression free survival ( PFS) and overall survival ( OS) were compared. Moreover, the adverse reaction was recorded. Results The median PFS and OS were 5. 0 and 8. 5 months in study group and 3. 5 and 8. 0 months in control group, respectively. The median PFS was higher in study group versus control group ( P〈0. 05) . No significant differences were observed on median OS between both groups. In addition, there were similar median PFS and OS between different chemotherapeutic efficacy of sub-group. The common adverse reaction included myelosuppression, fever, fatigue and joint pain. The differences of both groups were not statistically significant ( P〉0. 05) . Conclusion DC/CIK as the maintenance therapy can prolong the progression of advanced NSCLC patients in stable condition with tolerable and low adverse reaction.
出处
《临床肿瘤学杂志》
CAS
2014年第10期917-920,共4页
Chinese Clinical Oncology
关键词
树突状细胞
细胞因子诱导杀伤细胞
维持治疗
非小细胞肺癌
Dendritic cells Cytokine-induced killer cells Maintenance therapy Non-small cell lung cancer( NSCLC)